covered by

The relationship between atopic dermatitis and Staphylococcus aureus is longstanding and complex. A Dutch company is investing in a new technology that targets staph to help reduce disease severity. Approximately...

Gabriel Weston discovers an exciting new treatment for eczema that could also help us battle resistant bacteria.

Staphefekt, developed by the Dutch biotechnology company Micreos, is the world's first bacteria-killing enzyme targeting the Staphylococcus aureus-bacteria. It is available in Gladskin creams and gels for people with skin problems. ...

Imagine that you can target that specific bacterium which is responsible for causing redness, itch, pustules and pain. Without the negative side effects of antibiotics, which also kill the good...

Johan Frieling has recently been appointed as the new chief medical officer of Micreos. EPM talks to him about his experience in the pharmaceutical sector and the company’s new antibiotic...

Staphefekt™ has been shown to target the antibiotic resistant Staphylococcus aureus-bacteria. This can help millions of people world wide. Read the article on Newsweek